Achieve Life Sciences Inc (ACHV) Stock Analysis
Verdict: WATCH (do not buy)
Cytisinicline phase-3 momentum drives 90-day price strength, but a 5-month cash runway ($20.9M cash vs $49.5M annual burn) poses dilution risk.
Investment score: 44/100
Analysis as of
Is Achieve Life Sciences Inc stock worth reviewing? AI model thesis
The model assigns a HOLD recommendation with a score of 44/100. Strong clinical progress for cytisinicline is offset by short liquidity runway and impending equity dilution.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Achieve Life Sciences Inc opportunities and risks
What speaks for ACHV
- Cytisinicline Phase 3 Clinical Profile in Smoking Cessation
What speaks against ACHV
- Imminent Cash Depletion and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ACHV | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.7% |
| RIGL | 2.6x | 3.1x | 8.8x | 91.4% | 116.3% | 9.4% |
| DRUG.CN | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.0% |
| CLYM | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.5% |
| FDMT | n/a | 8.4x | n/a | 42.0% | -194.7% | -20.2% |
| DSGN | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.5% |
Frequently asked questions about Achieve Life Sciences Inc (ACHV)
Is ACHV stock a good investment?
The cached TradeMates AI model rates Achieve Life Sciences Inc as WATCH (do not buy) with an investment score of 44/100. The model assigns a HOLD recommendation with a score of 44/100. Strong clinical progress for cytisinicline is offset by short liquidity runway and impending equity dilution. This is algorithmic model output, not personal investment advice.
Is ACHV stock a buy?
The TradeMates model verdict for ACHV is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.